Business Combination (Tables)

9 Months Ended

Jun. 30, 2026

Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]

Schedule of Purchase Price

Components of the purchase price as set forth below (in thousands):


Purchase Price	Fair Value
Cash paid at closing	$	14,455
Transaction bonus paid	1,329
Transaction expense paid	133
Preexisting contractual liability settlement	13,841
Contingent consideration	2,483
	$	32,241
UK Biocentre cash balance at closing	$	4,767
Purchase price, net of cash acquired	$	27,474

Cash paid, net of cash acquired	$	11,150

Schedule of Tangible and Intangible Assets Acquired and Liabilities Assumed

The purchase price was allocated to UK Biocentre’s tangible and identifiable intangible assets acquired and liabilities assumed based on the estimated fair values as of March 4, 2026, as set forth below (in thousands):


Purchase Price Allocation	Fair Value
Accounts Receivable	$	2,053
Inventory	846
Other assets	795
Operating lease right-of-use assets	7,191
Property and Equipment	22,157
Identifiable Intangible Assets:
Trademarks	1,039
Accounts Payable	(930)
Accruals	(3,708)
Operating lease liabilities	(3,176)
Goodwill	1,207
Total purchase price, net of cash acquired	$	27,474

- Definition

Tabular disclosure of business combination. Includes, but is not limited to, recognized asset and liability.

+ References + Details